Financial Data and Key Metrics Changes - The company reported record net sales of $12.3 million for the quarter ended December 31, 2020, representing a year-over-year growth of 22% and a sequential increase of 5% [10][33] - Gross profit margins reached a record high of 72%, up from 64% in the prior year [10][35] - The operating loss was approximately $1.76 million, a significant improvement from a loss of $6.11 million in the prior year [36] - Non-GAAP adjusted operating loss decreased to $523,000 from $5 million in the first quarter of fiscal 2020 [37][38] - Cash and cash equivalents increased to $28.8 million, up from $14.8 million as of September 30, 2020 [41][44] Business Line Data and Key Metrics Changes - E-commerce sales hit a record high of $9.7 million, a 41% year-over-year increase, representing approximately 78% of total revenue [33] - The wholesale business generated $2.6 million in net sales, down from $3.2 million in the comparative quarter, attributed to the impact of COVID-19 on brick-and-mortar retailers [34] Market Data and Key Metrics Changes - The company ranks as one of the most visited CBD websites globally, according to SimilarWeb [8] - The customer retention rate increased over the prior quarter, driven by efforts to re-engage existing customers [20] - The average order value declined to just over $90, with a median purchase frequency of 39 days [21] Company Strategy and Development Direction - The company plans to expand into new product categories, including the launch of cbdMD Botanicals, targeting the beauty and skincare market [9][29] - The focus remains on direct-to-consumer e-commerce, which has shown significant growth [11] - The company aims to maintain gross profit margins between 65% and 70% while expanding its product portfolio and marketing efforts [35][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in gaining market share in the global CBD market and achieving positive non-GAAP adjusted operating income during the fiscal year [13] - The company is optimistic about the recovery of brick-and-mortar sales as larger retailers begin to reopen [49] - The management highlighted the importance of regulatory compliance and has engaged a former FDA official to oversee upcoming audits [14][15] Other Important Information - The company has made significant strides in international expansion, particularly in the Caribbean and Mexico [30] - cbdMD has received multiple awards for product quality and consumer satisfaction, reinforcing its brand reputation [27][28] Q&A Session Summary Question: Growth and Cash Utilization - A participant inquired about quarter-over-quarter growth and how the company plans to utilize its $28 million in cash for future growth [48] - Management responded that direct-to-consumer business remains strong, and they are focusing on smaller retailers while preparing for larger retailers' return [49][51] Question: Botanicals and New Demographics - The participant asked about the growth potential of the new Botanicals line targeting the female demographic [55] - Management indicated that marketing efforts are focused on this demographic and expressed optimism about retailer interest in the new product line [56][57]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-38299 cbdMD, INC. (Exact name of registrant as specified in its charter) North Carolina 47-3414576 (S ...

Financial Data and Key Metrics Changes - Total net sales for Q4 reached an all-time high of $11.7 million, representing a 23% year-over-year increase and a 10% sequential quarterly gain [31] - For the fiscal year ended September 30, total net sales were $41.9 million, a 77% increase over fiscal 2019 [31] - Direct-to-consumer sales hit a record high of $8.6 million in Q4, a 58% year-over-year increase, totaling $30.5 million for fiscal 2020, which is a 106% increase over fiscal 2019 [32][33] - Gross profit margin for Q4 was 54.4%, down from 56% in the prior year, while fiscal 2020 gross margin improved to 63% from 61.4% in fiscal 2019 [35] Business Line Data and Key Metrics Changes - The wholesale business generated $11.3 million in net sales for fiscal 2020, a 29% year-over-year increase, with Q4 showing a total of $3.1 million in net sales, representing a 29% sequential growth [34] - Paw CBD achieved net sales of approximately $4.5 million for fiscal 2020, with a focus on cross-selling and customer retention strategies [24][25] Market Data and Key Metrics Changes - The global CBD market is expected to grow from over $2 billion to over $10 billion by 2025, indicating significant growth potential [14] - The company has maintained a strong balance sheet with approximately $30 million in cash and virtually no debt, positioning itself favorably in the CBD industry [12] Company Strategy and Development Direction - The company plans to expand into new product categories to drive sales and diversify customer demographics [8] - Strategic partnerships with high-profile brands such as Joe Rogan Experience Podcast and Barstool Sports are expected to enhance brand recognition and customer acquisition [10][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive adjusted operating income in early fiscal 2021, despite potential delays due to marketing opportunities [13] - The regulatory environment for CBD remains uncertain, with no expected FDA guidance in the near future, prompting the company to focus on maintaining high manufacturing standards [16] Other Important Information - The company has made significant operational improvements, including moving to a larger fulfillment space and expanding lab capabilities [45] - The company ended the fiscal year with $14.8 million in cash and cash equivalents, providing ample capital for future strategies [37] Q&A Session Summary Question: What new products can be expected in the coming quarters? - The company plans to roll out new product lines and expand partnerships with larger brands to enhance brand value and recognition [49][50] Question: Is there exclusivity in the Joe Rogan and Barstool Sports partnerships? - The Joe Rogan partnership is exclusive for 2021, while the Barstool partnership is not exclusive but remains strong [60] Question: How does the company view multi-level marketing competitors? - The company does not see multi-level marketing as direct competition due to differences in branding focus and distribution channels [61][62] Question: What growth is expected for the Paw brand in 2021? - While no specific guidance was provided, significant growth is anticipated in the Paw brand due to limited competition in the CBD pet market [65]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-38299 CBDMD, INC. (Exact name of registrant as specified in its charter) North Carolina 47-3414576 (State ...

cbdMD, Inc. (NYSE:YCBD) Q3 2020 Results Earnings Conference Call August 12, 2020 4:15 PM ET Company Participants Mark Elliott - CFO and COO Marty Sumichrast - Chairman and Co CEO Ken Cohn - Chief Marketing Officer Lance Blundell - General Counsel Conference Call Participants Paul Cooney - Joseph Gunnar Aaron Grey - Alliance Global Partners Scott Fortune - Roth Capital Partners Gerald Pascarelli - Cowen Operator Good afternoon. And welcome to the cbdMD Third Quarter Fiscal 2020 Earnings Call and Update. Th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) North Carolina 47-3414576 State ...

cbdMD, Inc. (NYSE:YCBD) Q2 2020 Earnings Conference Call May 18, 2020 1:45 PM ET Company Participants Marty Sumichrast - Chairman and Co CEO Mark Elliott - CFO and COO Conference Call Participants Scott Fortune - Roth Capital Partners Paul Cooney - Joseph Gunnar Michael Lavery - Piper Sandler Pablo Zuanic - Cantor Fitzgerald Bill Sutherland - Benchmark Paul Bornstein - Black Diamond Daby Carreras - Spartan Capital Steve Emerson - Emerson Investments Operator Good afternoon. And welcome to the cbdMD Secon ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) North Carolina 47-3414576 State ...

cbdMD, Inc. (NYSE:YCBD) Q1 2020 Earnings Conference Call February 13, 2020 4:15 PM ET Company Participants Mark Elliott – Chief Financial Officer Marty Sumichrast – Chairman and Co-Chief Executive Officer Conference Call Participants Bill Sutherland – Benchmark Scott Rothbaum – Joseph Gunnar Barry Rubin – Private Investor Operator Good afternoon. Welcome to the cbdMD First Quarter Fiscal 2020 Earnings Call and Update. This afternoon, the company issued a press release that provided an overview of its first ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) North Carolina 47-3414576 St ...